INVENTIVA SA - ADR (IVA) Stock Price, Quote, News and Overview
NASDAQ:IVA - Nasdaq - US46124U1079 - ADR - Currency: USD
IVA Quote, Performance and Key Statistics
3.56
+0.2 (+5.95%)
The current stock price of IVA is 3.56 USD. In the past month the price increased by 26.24%. In the past year, price increased by 9.54%.
IVA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.81 | 301.01B | ||
| AMGN | AMGEN INC | 13.81 | 147.14B | ||
| GILD | GILEAD SCIENCES INC | 22.63 | 130.06B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1646.62 | 122.76B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.3 | 61.38B | ||
| ARGX | ARGENX SE - ADR | 320.27 | 36.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.28B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.70B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.47B | ||
| NTRA | NATERA INC | N/A | 19.23B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.60B | ||
| BIIB | BIOGEN INC | 7.07 | 17.05B |
Related stock screener links
About IVA
Company Profile
Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. The company is headquartered in Daix, Occitanie. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
Company Info
INVENTIVA SA - ADR
50 rue de Dijon, Daix
Daix OCCITANIE 21121 FR
CEO: Frederic Cren
Employees: 122
Company Website: https://inventivapharma.com/
Investor Relations: https://inventivapharma.com/investors/
Phone: 33380447500
INVENTIVA SA - ADR / IVA FAQ
What is the stock price of INVENTIVA SA - ADR today?
The current stock price of IVA is 3.56 USD. The price increased by 5.95% in the last trading session.
What is the ticker symbol for INVENTIVA SA - ADR stock?
The exchange symbol of INVENTIVA SA - ADR is IVA and it is listed on the Nasdaq exchange.
On which exchange is IVA stock listed?
IVA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for INVENTIVA SA - ADR stock?
12 analysts have analysed IVA and the average price target is 10.17 USD. This implies a price increase of 185.72% is expected in the next year compared to the current price of 3.56. Check the INVENTIVA SA - ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is INVENTIVA SA - ADR worth?
INVENTIVA SA - ADR (IVA) has a market capitalization of 186.41M USD. This makes IVA a Micro Cap stock.
How many employees does INVENTIVA SA - ADR have?
INVENTIVA SA - ADR (IVA) currently has 122 employees.
What are the support and resistance levels for INVENTIVA SA - ADR (IVA) stock?
INVENTIVA SA - ADR (IVA) has a support level at 3.2. Check the full technical report for a detailed analysis of IVA support and resistance levels.
Is INVENTIVA SA - ADR (IVA) expected to grow?
The Revenue of INVENTIVA SA - ADR (IVA) is expected to grow by 150.88% in the next year. Check the estimates tab for more information on the IVA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy INVENTIVA SA - ADR (IVA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of IVA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of IVA, evaluating the profitability, health, valuation and growth aspects
- INVENTIVA SA - ADR (IVA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- INVENTIVA SA - ADR (IVA) Sales and EPS estimates to see what analysts future expectations are.
- INVENTIVA SA - ADR (IVA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- INVENTIVA SA - ADR (IVA) Insider and Institutional Ownership to learn about the owners and their transactions.
- INVENTIVA SA - ADR (IVA) Stock Chart to make your own analysis
- INVENTIVA SA - ADR (IVA) Latest news and press-releases to stay up to date.
Does INVENTIVA SA - ADR (IVA) stock pay dividends?
IVA does not pay a dividend.
When does INVENTIVA SA - ADR (IVA) report earnings?
INVENTIVA SA - ADR (IVA) will report earnings on 2025-07-29.
What is the Price/Earnings (PE) ratio of INVENTIVA SA - ADR (IVA)?
INVENTIVA SA - ADR (IVA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.32).
What is the Short Interest ratio of INVENTIVA SA - ADR (IVA) stock?
The outstanding short interest for INVENTIVA SA - ADR (IVA) is 0.86% of its float. Check the ownership tab for more information on the IVA short interest.
IVA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to IVA. When comparing the yearly performance of all stocks, IVA is one of the better performing stocks in the market, outperforming 95.22% of all stocks.
IVA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to IVA. IVA has a bad profitability rating. Also its financial health evaluation is rather negative.
IVA Financial Highlights
Over the last trailing twelve months IVA reported a non-GAAP Earnings per Share(EPS) of -4.32. The EPS decreased by -20.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -264.26% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
IVA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to IVA. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 56.03% and a revenue growth 150.88% for IVA